Press Releases

BOSTON and SYDNEY — 20 September 2019 AEST — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces, in accordance with ASX Listing Rule 3.16.4, that it has entered into a revised...

BOSTON and SYDNEY — 20 September 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier...

BOSTON and SYDNEY — 22 August 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a financing (Financing) with Crystal Amber...

BOSTON and SYDNEY — 31 July 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the execution of its contract with Surgical Specialists of Louisiana in Metairie, Louisiana, as a clinical...

BOSTON and SYDNEY — 23 July 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce execution of its contract with Thomas Jefferson University in Philadelphia, Pennsylvania as the fourth...

BOSTON and SYDNEY — 11 July 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the execution of its contract with Brigham and Women’s Hospital in Boston, Massachusetts as the lead...

BOSTON and SYDNEY – 2 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity confirms that, following the Company’s announcement on 1 July 2019, it has today issued a total of 453,609,963 CHESS...

BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company) medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity confirms that, following the holding of its 2019 Annual Meeting of Stockholders, it has issued certain warrants...

BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company) held its Annual Meeting of Stockholders on 30 June 2019 and in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Proxy Statement dated 20...

BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the Maturity Date...